B.06 Safety and Efficacy of Nusinersen in Infants/Children With Spinal Muscular Atrophy (SMA): Part 1 of the Phase 2 EMBRACE Study

Canadian Journal of Neurological Sciences - United Kingdom
doi 10.1017/cjn.2018.94
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Cambridge University Press (CUP)

Related search

Cost of Illness of Spinal Muscular Atrophy (SMA) in Italy

Global and Regional Health Technology Assessment
Health Policy
2019English

Spinal Muscular Atrophy Type 1

Pediatric Critical Care Medicine
Child HealthCritical CarePediatricsPerinatologyIntensive Care Medicine
2012English

Efficacy and Safety of Dutasteride in Patients With Spinal and Bulbar Muscular Atrophy: A Randomised Placebo-Controlled Trial

The Lancet Neurology
Neurology
2011English

NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen Further Ameliorates Spinal Muscular Atrophy in Mice

American Journal of Human Genetics
Genetics
2019English

Respiratory Management of the Infant With Type 1 Spinal Muscular Atrophy

Archives of Disease in Childhood
Child HealthPediatricsPerinatology
2005English

ECG in Neonate Mice With Spinal Muscular Atrophy Allows Assessment of Drug Efficacy

Frontiers in Bioscience - Elite
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2015English

014 AVXS-101 Gene-Replacement Therapy (GRT) in Presymptomatic Spinal Muscular Atrophy (SMA): Study Update

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2019English

P.065 AVXS-101 Gene-Replacement Therapy (GRT)) in Presymptomatic Spinal Muscular Atrophy (SMA): Study Update

Canadian Journal of Neurological Sciences
MedicineNeurology
2019English

Reliability of the Modified Hammersmith Functional Motor Scale in Young Children With Spinal Muscular Atrophy

Muscle and Nerve
Molecular NeuroscienceNeurologyPhysiologyCellular
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy